Dec 15, 2022 7:00 am EST Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
Nov 9, 2022 4:05 pm EST Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Oct 20, 2022 7:00 am EDT Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
Sep 15, 2022 4:05 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
May 12, 2022 4:05 pm EDT Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
